Title : An enteric capsule for oral drug delivery made from natural materials
Abstract:
Apillet has developed a unique Oral drug delivery concept (APIVault) which enable targeted release in the intestine of Sensitive (bio)pharmaceuticals, Probiotics and Nutraceuticals. Such compounds are prone to degradation in the stomach and must be protected by a gastro-resistant encapsulation to pass the stomach to maintain efficacy/efficiency. The APIVault capsule can, in different formats, be programmed for enteric release in the upper parts of the small intestine or for late release in the colon. There is a strong commercial and clinical need for a gastro-resistant enteric encapsulation made from safe bio-inactive materials (GRAS). The enteric encapsulations currently in use is not approved for human consumption without a doctor’s prescription. This makes them unwanted for delivery of many compounds e.g Enzyme treatments, Probiotics and Nutraceuticals. The patented APIVault technology utilizes that bacterial cellulose (BC) isn’t digested in the gastrointestinal (GI) tract but BC can protect drugs in the harsh conditions during stomach passing. Moreover, certain cellulase enzymes are inactive in the acidic stomach, but digest cellulose in the pH neutral intestine. By combining BC with a cellulase, a BC/cellulase combo material with enteric properties is obtained. The APIVault combo capsule is engineered to have highly manageable drug release properties.
Data on the technology and the enteric release properties of the APIVault encapsulations will be presented.
Apillet has a significant innovation pipeline in the field of enteric encapsulations. This enables a sustained business development of the company.
Audience Take Away Notes:
- Learn about the targeted enteric delivery landscape
- The APIVault enteric encapsulation is suitable for the development of a wide range of Sensitive (bio) pharmaceuticals, Probiotics, Nutraceuticals, and Vaccines
- The encapsulation is engineered to have highly manageable release properties and can be designed to deliver in the small intestine or later in the colon
- APIVault is made from safe natural materials approved as a novel food by regulatory bodies and thus is expected to have a relatively simple medicinal regulatory path
